Concepedia

Publication | Open Access

Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors

DOIFull Paper Access

66

Citations

42

References

2021

Year

Naoko Takebe, Abdul Rafeh Naqash, Geraldine O’Sullivan Coyne, Shivaani Kummar, T. Khanh, Ashley Bruns, Lamin Juwara, Jennifer Zlott, Larry Rubinstein, Richard Piekarz,
Clinical Cancer Research

Abstract

We determined the once-daily adavosertib RPh2D and observed activity in patients with ovarian or endometrial carcinoma, including two with baseline <i>CCNE1</i> mRNA overexpression. Future studies will determine whether <i>CCNE1</i> overexpression is a predictive biomarker for adavosertib.

References

YearCitations

Page 1